Guangdong Marubi Biotechnology Co., Ltd.

SHSE:603983 Stock Report

Market Cap: CN¥12.4b

Guangdong Marubi Biotechnology Valuation

Is 603983 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 603983 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 603983 (CN¥30.8) is trading above our estimate of fair value (CN¥23.21)

Significantly Below Fair Value: 603983 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 603983?

Key metric: As 603983 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 603983. This is calculated by dividing 603983's market cap by their current earnings.
What is 603983's PE Ratio?
PE Ratio38.1x
EarningsCN¥324.39m
Market CapCN¥12.35b

Price to Earnings Ratio vs Peers

How does 603983's PE Ratio compare to its peers?

The above table shows the PE ratio for 603983 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average37.3x
003006 Chongqing Baiya Sanitary Products
38.8x26.1%CN¥11.4b
603193 Runben Biotechnology
32x22.7%CN¥9.8b
300957 Yunnan Botanee Bio-Technology GroupLTD
35.3x33.3%CN¥20.9b
600315 Shanghai Jahwa United
43.2x27.5%CN¥11.6b
603983 Guangdong Marubi Biotechnology
38.1x24.0%CN¥12.4b

Price-To-Earnings vs Peers: 603983 is expensive based on its Price-To-Earnings Ratio (38.1x) compared to the peer average (37.3x).

Price to Earnings Ratio vs Industry

How does 603983's PE Ratio compare vs other companies in the CN Personal Products Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
603983 38.1xIndustry Avg. 34.7xNo. of Companies5PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 603983 is expensive based on its Price-To-Earnings Ratio (38.1x) compared to the CN Personal Products industry average (34.7x).

Price to Earnings Ratio vs Fair Ratio

What is 603983's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

603983 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio38.1x
Fair PE Ratio27.8x

Price-To-Earnings vs Fair Ratio: 603983 is expensive based on its Price-To-Earnings Ratio (38.1x) compared to the estimated Fair Price-To-Earnings Ratio (27.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 603983 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥30.80
CN¥31.54
+2.4%
16.7%CN¥36.64CN¥19.00n/a8
Nov ’25CN¥29.66
CN¥30.43
+2.6%
16.6%CN¥35.50CN¥19.00n/a8
Oct ’25CN¥28.81
CN¥28.40
-1.4%
15.6%CN¥33.90CN¥19.00n/a8
Sep ’25CN¥22.03
CN¥28.63
+30.0%
16.4%CN¥33.90CN¥19.00n/a7
Aug ’25CN¥22.43
CN¥33.43
+49.0%
14.5%CN¥40.40CN¥25.00n/a7
Jul ’25CN¥27.58
CN¥33.43
+21.2%
14.5%CN¥40.40CN¥25.00n/a7
Jun ’25CN¥30.05
CN¥33.43
+11.2%
14.5%CN¥40.40CN¥25.00n/a7
May ’25CN¥30.33
CN¥31.61
+4.2%
17.1%CN¥39.30CN¥23.40n/a7
Apr ’25CN¥29.47
CN¥29.82
+1.2%
21.1%CN¥39.30CN¥22.00n/a8
Mar ’25CN¥31.57
CN¥29.82
-5.6%
21.1%CN¥39.30CN¥22.00n/a8
Feb ’25CN¥29.43
CN¥28.86
-1.9%
21.4%CN¥39.30CN¥22.00n/a8
Jan ’25CN¥25.27
CN¥28.86
+14.2%
21.4%CN¥39.30CN¥22.00n/a8
Dec ’24CN¥26.30
CN¥29.61
+12.6%
19.0%CN¥39.30CN¥23.00n/a8
Nov ’24CN¥27.81
CN¥30.00
+7.9%
22.4%CN¥43.40CN¥22.40CN¥29.668
Oct ’24CN¥24.72
CN¥31.12
+25.9%
21.4%CN¥43.40CN¥22.40CN¥28.818
Sep ’24CN¥27.05
CN¥31.49
+16.4%
23.9%CN¥47.00CN¥23.00CN¥22.038
Aug ’24CN¥29.70
CN¥33.29
+12.1%
28.1%CN¥47.00CN¥22.00CN¥22.439
Jul ’24CN¥32.35
CN¥33.29
+2.9%
28.1%CN¥47.00CN¥22.00CN¥27.589
Jun ’24CN¥34.10
CN¥33.29
-2.4%
28.1%CN¥47.00CN¥22.00CN¥30.059
May ’24CN¥36.24
CN¥30.78
-15.1%
25.8%CN¥43.00CN¥19.30CN¥30.339
Apr ’24CN¥38.15
CN¥30.54
-20.0%
24.8%CN¥40.40CN¥19.30CN¥29.479
Mar ’24CN¥39.14
CN¥30.54
-22.0%
24.8%CN¥40.40CN¥19.30CN¥31.579
Feb ’24CN¥33.27
CN¥30.54
-8.2%
24.8%CN¥40.40CN¥19.30CN¥29.439
Jan ’24CN¥33.74
CN¥28.85
-14.5%
25.7%CN¥40.40CN¥19.30CN¥25.278
Dec ’23CN¥36.82
CN¥27.04
-26.6%
22.2%CN¥40.00CN¥19.30CN¥26.309
Nov ’23CN¥29.44
CN¥24.84
-15.6%
17.0%CN¥31.62CN¥19.30CN¥27.819

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

SYoung Group

CN¥5.0b

Engages in the research and development, production, and sale of cosmetic products in China.

300740

CN¥12.82

7D

-7.7%

1Y

-19.4%

Sirio Pharma

CN¥6.2b

Operates as a contract manufacturer for dietary supplement industry worldwide.

300791

CN¥26.60

7D

-5.6%

1Y

2.7%

Byhealth

CN¥21.7b

Develops and sells dietary supplements.

300146

CN¥12.90

7D

-5.4%

1Y

-28.4%